Arvinas (ARVN) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Does the media prefer RXRX or ARVN?

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 6 articles in the media. Recursion Pharmaceuticals' average media sentiment score of 1.24 beat Arvinas' score of 0.33 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is RXRX or ARVN more profitable?

Arvinas has a net margin of -75.51% compared to Recursion Pharmaceuticals' net margin of -579.52%. Arvinas' return on equity of -33.75% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Arvinas	-75.51%	-33.75%	-16.75%

Do analysts prefer RXRX or ARVN?

Recursion Pharmaceuticals currently has a consensus target price of $7.60, suggesting a potential upside of 81.60%. Arvinas has a consensus target price of $20.92, suggesting a potential upside of 220.41%. Given Arvinas' stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Arvinas	0 Sell rating(s)	8 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.60

Which has higher earnings and valuation, RXRX or ARVN?

Arvinas has higher revenue and earnings than Recursion Pharmaceuticals. Arvinas is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$59.82M	28.44	-$328.07M	-$1.77	-2.36
Arvinas	$426.90M	1.12	-$198.90M	-$0.66	-9.89

Do insiders & institutionals have more ownership in RXRX or ARVN?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in RXRX or ARVN?

Arvinas received 172 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 65.81% of users gave Arvinas an outperform vote while only 56.14% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 32 56.14%	Underperform Votes 25 43.86%
Arvinas	Outperform Votes 204 65.81%	Underperform Votes 106 34.19%

Which has more volatility and risk, RXRX or ARVN?

Recursion Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.

Summary

Arvinas beats Recursion Pharmaceuticals on 14 of the 17 factors compared between the two stocks.